In:
Radiation Oncology, Springer Science and Business Media LLC, Vol. 6, No. 1 ( 2011-12)
Kurzfassung:
Perifosine is a membrane-targeted alkylphospholipid developed to inhibit the PI3K/Akt pathway and has been suggested as a favorable candidate for combined use with radiotherapy. In this study, we investigated the effect of the combined treatment of perifosine and radiation (CTPR) on prostate cancer cells in vitro and on prostate cancer xenografts in vivo . Methods Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR. Clonogenic survival assays, sulforhodamine B cytotoxity assays and cell density assays were used to assess the effectiveness of each therapy in vitro . Measurements of apoptosis, cell cycle analysis by flow cytometry and Western blots were used to evaluate mechanisms of action in vitro . Tumor growth delay assays were used to evaluate radiation induced tumor responses in vivo . Results In vitro , CTPR had greater inhibitory effects on prostate cancer cell viability and clonogenic survival than either perifosine or radiation treatment alone. A marked increase in prostate cancer cell apoptosis was noted in CTPR. Phosphorylation of AKT-T308 AKT and S473 were decreased when using perifosine treatment or CTPR. Cleaved caspase 3 was significantly increased in the CTPR group. In vivo , CTPR had greater inhibitory effects on the growth of xenografts when compared with perifosine or radiation treatment alone groups. Conclusions Perifosine enhances prostate cancer radiosensitivity in vitro and in vivo . These data provide strong support for further development of this combination therapy in clinical studies.
Materialart:
Online-Ressource
ISSN:
1748-717X
DOI:
10.1186/1748-717X-6-39
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2011
ZDB Id:
2224965-5
